Boston, MA 09/16/2014 (wallstreetpr) – The stock of Avanir Pharmaceuticals Inc (NASDAQ:AVNR) is on the soaring spree. At the end of day’s trade on September 15, AVNR gained a whopping 5.75, i.e. around 85.31% of its net per unit dollar value. The organization notched up positive Phase II results pertaining to its renowned drug – AVP- 923.
This is a great feat attained by Avanir Pharmaceuticals Inc (NASDAQ:AVNR) since this drug intends to provide a tongue-in-check portrayal of the efficiency with which it helps reduce the level of aggression and agitation and ensure better safety measures for patients crippled by the fomenting Alzheimer’s disease!
The Disorder Of Disdain
The trial focused on how the placebo drug efficaciously worked upon individuals based on Neuropsychiatric Inventory or NPI. The trial ran quite well, within the apt time period and there were no hideous repercussions of the drug upon the subjects. It is often stated that Alzheimer’s disease has no prudent practice in vogue that could come as a respite to quell the sufferings of over 6 million people solely in the US, facing the treacherous disorder – Alzheimer’s disease. The disease rampantly develops at a rapid pace amongst the aged population. By FY 2016, the net number of people expected to suffer at the current rate is deemed to escalate to 16 million.
Views And Reviews
At the given rate, the prominence of AVP-923 is invariably of utmost importance. If the drug succeeds in launching into the market right in time, the Avanir Pharmaceuticals Inc (NASDAQ:AVNR) shall be duly benefited as the sales of the drug is liable to propel significantly. At such a premise, the overall revenues garnered are ought to rise, given the swelling markets, which constitute individuals in need of the drug!
Jeffrey Cummings – MD and Director of the Cleveland Clinic Lou Ruvo Center for Brain Health –the chairman of the committee associated with study steering, conjectured that the successful trial is indeed an exciting proposition and can quell the distresses of affected families, increasing the company’s revenues in return.
